Description
The Diabetes Autoantibody Panel is a specialized blood test used to detect the presence of specific autoantibodies that indicate type 1 diabetes or a risk of developing it in the future. These autoantibodies are markers of autoimmune activity where the body’s immune system mistakenly attacks the insulin-producing beta cells in the pancreas.
Purpose of the Test
- Diagnose type 1 diabetes, especially in individuals with atypical symptoms
- Distinguish between type 1 and type 2 diabetes
- Identify risk of type 1 diabetes in at-risk individuals (e.g., those with a family history)
- Assess individuals with latent autoimmune diabetes in adults (LADA), a slower-onset form of type 1 diabetes often misdiagnosed as type 2
Autoantibodies Tested in This Panel
1. Islet Cell Cytoplasmic Autoantibodies (ICA)
- Target pancreatic islet cells
- Present in ~70-80% of individuals with new-onset type 1 diabetes
2. Glutamic Acid Decarboxylase Autoantibodies (GADA or anti-GAD)
- Target the enzyme GAD found in beta cells
- Often present in both children and adults with autoimmune diabetes
3. Insulinoma-Associated-2 Autoantibodies (IA-2A)
- Target a protein (IA-2) involved in insulin secretion
- Often seen in newly diagnosed cases of type 1 diabetes
4. Insulin Autoantibodies (IAA)
- Target insulin itself
- Common in young children with type 1 diabetes, especially before insulin therapy begins
What the Results Can Show
- Positive for one or more antibodies: Indicates autoimmune activity against pancreatic beta cells and supports a diagnosis of type 1 diabetes or high risk for developing it.
- Negative for all antibodies: More likely to be type 2 diabetes or another non-autoimmune form of diabetes.
- Antibodies may be present years before symptoms of type 1 diabetes appear.
Benefits of the Test
- Clarifies diagnosis: Helpful in cases where symptoms of type 1 and type 2 diabetes overlap
- Enables early monitoring: If detected early in high-risk individuals, it allows for proactive management
- Guides treatment: Type 1 diabetes requires insulin therapy, while type 2 may respond to lifestyle changes or oral medications
Fasting Requirements
- Fasting is not required for this test
Who Should Consider This Test?
- Individuals with new-onset diabetes under age 30
- Adults with diabetes who are not responding well to oral medications
- People with a family history of type 1 diabetes
- Children or siblings of individuals with type 1 diabetes as part of screening or clinical studies

